Boynton Beach Defective Drug Lawyer — Taking on Pharmaceutical Companies When Their Drugs Cause Harm

You trusted a drug to help you. Your doctor prescribed it, or you bought it over the counter, relying on the manufacturer’s assurance that it was safe and effective when used as directed. Then something went wrong — a side effect no one warned you about, a contaminated batch, an injury that the company knew was possible but chose not to disclose. Now you are facing medical bills, lost income, and a pharmaceutical company with virtually unlimited legal resources standing between you and accountability.

Defective drug cases are among the most complex in personal injury law. They span FDA regulatory law, Florida product liability statutes, pharmaceutical chemistry, and — increasingly — federal Multi-District Litigation (MDL) proceedings that consolidate thousands of claims nationwide. Palm Beach County plaintiffs harmed by defective drugs have a particular connection to one of the country’s largest active pharmaceutical MDLs: the Zantac (ranitidine) MDL No. 2924, which has been litigated in the U.S. District Court for the Southern District of Florida in West Palm Beach.

The Law Offices of Wolf & Pravato have represented injured individuals and families throughout South Florida for over 75 years. Our Boynton Beach office at 1375 Gateway Blvd. serves clients across Palm Beach County in product liability and defective drug cases. With over $200 million recovered for our clients and membership in the Million Dollar Advocates Forum, we have the resources and track record to go up against the largest pharmaceutical manufacturers — and we do so on a pure contingency basis: no fee unless we win.

What Is Defective Drug Liability Under Florida Law?

Florida follows the strict liability doctrine for defective product claims, including defective drugs. Under strict liability — codified in Florida’s product liability framework and grounded in §768.81 F.S. — a manufacturer, distributor, or seller of a defective product can be held liable for injuries caused by that product without the injured person needing to prove that the company acted negligently. The focus is on the product itself: was it defective, and did that defect cause the injury?

For pharmaceutical products specifically, Florida courts apply the Restatement (Second) of Torts §402A framework, which has been extended and refined through decades of case law. Drug manufacturers are held to a high standard: they are required to design products that are reasonably safe for their intended use, manufacture them without contamination or error, and warn prescribers and patients of all known material risks.

Defective drug claims in Florida fall into three distinct legal categories, each requiring different evidence and expert support:

1. Design Defect — The Drug Was Inherently Dangerous

A design defect claim alleges that the pharmaceutical compound itself — as conceived and approved — was unreasonably dangerous to users. This is the most difficult category to prove because FDA approval creates a regulatory presumption of reasonable safety (though not an absolute defense). Design defect claims typically require expert pharmacologists and toxicologists to testify that the drug’s risk-benefit profile fell below an acceptable standard and that safer alternative designs or formulations existed.

The Zantac (ranitidine) litigation is the most prominent current example of a design defect claim in the pharmaceutical space. Plaintiffs alleged that ranitidine’s molecular structure causes it to degrade into N-Nitrosodimethylamine (NDMA) — a probable human carcinogen — during normal digestion and storage, making the drug inherently defective at the design level. The MDL for these claims, No. 2924, was presided over by U.S. District Judge Robin L. Rosenberg in the Southern District of Florida — the same federal courthouse that covers Palm Beach County.

2. Manufacturing Defect — A Good Drug Made Badly

A manufacturing defect claim does not challenge the drug’s underlying design — it alleges that a specific batch, lot, or unit of the drug deviated from the approved design due to a production error, contamination, improper storage, or quality control failure. The drug was designed safely, but this particular product was not manufactured to that safe specification.

Manufacturing defect cases in pharmaceuticals arise from:

• Contamination during production — bacterial, chemical, or particulate contamination in a manufacturing facility
• Incorrect active ingredient concentration — a batch that contains too much or too little of the active compound
• Cross-contamination between products in multi-drug manufacturing facilities
• Improper storage or distribution conditions that degrade a drug before it reaches the patient — particularly relevant in South Florida’s high-heat environment, where temperature-sensitive medications can deteriorate in supply chain gaps
• Mislabeling — the wrong drug, wrong strength, or wrong instructions in a package

3. Failure to Warn — Knowing the Risk and Hiding It

Failure to warn is the most frequently litigated theory in pharmaceutical product liability — and often the most powerful. It alleges that the manufacturer knew (or should have known) about a material risk associated with the drug and failed to adequately disclose it to prescribing physicians and patients.

The FDA regulates drug labeling through a complex system of required warnings. The most serious warning mechanism is the Black Box Warning — the strongest safety communication the FDA requires — which must appear prominently on drug labeling when there is evidence of a serious or life-threatening risk. Failure to warn claims in pharmaceuticals typically allege:

• The company was aware of adverse event reports, clinical trial data, or post-market surveillance data that revealed a serious risk, but failed to update labeling
• The company delayed seeking a Black Box Warning or label update despite internal knowledge of the risk
• The warnings provided were vague, buried in fine print, or written in language that a prescribing physician would not recognize as signaling a serious hazard
• The company actively promoted off-label uses without disclosing associated risks

Florida applies the learned intermediary doctrine to failure-to-warn claims involving prescription drugs: the manufacturer’s duty to warn runs to the prescribing physician (the “learned intermediary”), not directly to the patient. This means the manufacturer can satisfy its warning duty by adequately informing the prescribing doctor of the risks — even if the patient was never told. However, the learned intermediary doctrine has exceptions, including when the manufacturer directly markets to consumers (direct-to-consumer advertising), which is extremely common for major pharmaceutical brands.

The FDA’s Role in Defective Drug Cases — Recalls, Black Box Warnings, and What They Mean for Your Claim

The U.S. Food and Drug Administration (FDA) is the primary federal regulator of pharmaceutical safety. Understanding how the FDA operates — and how its actions create or limit legal claims — is essential to understanding defective drug litigation.

FDA Drug Approval: Not a Guarantee of Safety

FDA approval does not mean a drug is perfectly safe. It means the FDA determined, based on pre-approval clinical trial data, that the drug’s benefits outweigh its risks for the approved indication. However, pre-approval clinical trials typically involve thousands of participants over months or years — far too limited a dataset to detect rare adverse events that may only emerge after millions of patients use the drug over decades. Post-market surveillance is supposed to catch these risks, but reporting systems are voluntary for many participants in the supply chain and historically underutilized.

FDA approval also creates a legal complication for certain claims. Federal law — specifically the preemption doctrine — can shield generic drug manufacturers from some state-law failure-to-warn claims because generic manufacturers are legally required to use the same labeling as the brand-name drug. Brand-name manufacturers, by contrast, have greater flexibility to update labeling and face fewer preemption barriers. This is why, in the Zantac MDL, brand-name manufacturer claims proceeded while generic claims were dismissed on preemption grounds.

FDA Drug Recalls: Class I, II, and III

When the FDA identifies a safety problem with a marketed drug, it may issue a recall — either voluntary (at the manufacturer’s request) or mandatory (ordered by the FDA). Recalls are classified by severity:

• Class I Recall: The most serious — use of or exposure to the product will cause serious adverse health consequences or death
• Class II Recall: Use of or exposure to the product may cause temporary adverse health consequences; serious adverse health consequences are remote
• Class III Recall: Use of or exposure to the product is not likely to cause adverse health consequences, but the product violates FDA labeling or manufacturing regulations

An FDA recall does not automatically win your lawsuit — but it is powerful evidence. A Class I recall establishes that the FDA itself determined the product was dangerous, which directly supports the defect element of your claim. The timing of the recall relative to when the manufacturer learned of the risk is often central to failure-to-warn litigation: companies that knew about a safety issue but delayed recall initiation face significant liability exposure.

Boynton Beach and Palm Beach County residents can check current FDA drug recalls, market withdrawals, and safety alerts directly on the FDA’s official drug recall database. If you believe you have been harmed by a drug that has been recalled or that carries an updated Black Box Warning, contact Wolf & Pravato immediately.

Black Box Warnings and Failure to Warn Claims

A Black Box Warning (named for the prominent black border required on the label) is the FDA’s strongest mandatory warning mechanism. It is required when clinical studies show that a drug can cause serious adverse reactions, including life-threatening events. When a drug causes you harm that is addressed in a Black Box Warning, your failure-to-warn claim may succeed if you can prove the warning was inadequate, not prominently disclosed, or added too late after the manufacturer had knowledge of the risk.

Mass Tort and MDL Litigation — How Most Major Defective Drug Cases Actually Work

One of the most important things a defective drug victim in Boynton Beach needs to understand is how large pharmaceutical cases are actually litigated. Unlike a typical car accident case that proceeds in Palm Beach County’s 15th Judicial Circuit from start to finish, major pharmaceutical product liability cases involving thousands or millions of victims are almost always consolidated into either a Multi-District Litigation (MDL) in federal court or a coordinated class action proceeding.

What Is MDL (Multi-District Litigation)?

When thousands of plaintiffs across the country file similar lawsuits against the same pharmaceutical manufacturer in federal courts, the Judicial Panel on Multidistrict Litigation (JPML) can consolidate those cases before a single federal judge for pretrial proceedings — discovery, motions, and bellwether trials. The purpose is efficiency: rather than thousands of courts independently obtaining the same documents and hearing the same expert testimony, one judge manages all of it.

Critically, in an MDL, each plaintiff retains their individual lawsuit. This is different from a class action. Your case is consolidated with thousands of others for pretrial purposes, but you have your own claim with your own damages. Bellwether trials — where a small number of representative cases are tried to give both sides a sense of how juries respond to the evidence — are used to drive global settlement negotiations.

The Zantac MDL: A Florida-Based Pharmaceutical Litigation of National Importance

The most significant active pharmaceutical MDL for Palm Beach County residents has been the Zantac (ranitidine) Products Liability Litigation, MDL No. 2924, litigated before U.S. District Judge Robin L. Rosenberg in the Southern District of Florida in West Palm Beach. This MDL involves allegations that ranitidine — the active ingredient in Zantac and generic equivalents — degrades into NDMA, a probable human carcinogen, linking long-term Zantac use to bladder, stomach, and other cancers.

The litigation history is instructive for any pharmaceutical injury victim:

• September 2019: FDA announces testing found NDMA in Zantac products; voluntary recalls begin
• April 2020: FDA requests all ranitidine products be removed from the market
• February 2020: MDL No. 2924 formed and assigned to the Southern District of Florida
• December 2022: Judge Rosenberg dismisses federal MDL claims after excluding plaintiffs’ experts under Rule 702 — a Daubert challenge based on the reliability of causation expert testimony
• 2023–2024: State court cases proceed; GSK agrees to pay up to $2.2 billion to settle approximately 80,000 state court Zantac cases; Sanofi settles for $200–$250 million
• 2024: Jury in a California Zantac trial found Boehringer Ingelheim failed to adequately warn consumers — a split verdict on causation but a finding of failure to warn

The Zantac MDL story illustrates three lessons that apply to every pharmaceutical case: (1) FDA approval does not shield a manufacturer from liability for failure to warn of known risks; (2) the quality of expert scientific testimony is often the decisive factor in pharmaceutical litigation; and (3) even when a federal MDL is dismissed, state court cases may proceed on different legal theories and evidentiary standards.

Currently Active Pharmaceutical Litigations Affecting Florida Residents

Beyond Zantac, Wolf & Pravato monitors and evaluates the following active or recently resolved pharmaceutical litigations for potential Boynton Beach and Palm Beach County clients:

• CPAP/BiPAP Device Recall (Philips Respironics): Millions of machines recalled due to degradation of polyurethane foam, which can release carcinogenic particles into the airway. MDL proceedings active in the Western District of Pennsylvania.
• Tylenol (acetaminophen) and autism/ADHD: Litigation alleging prenatal acetaminophen use is linked to autism spectrum disorder and ADHD in children. State and federal cases consolidated in MDL No. 3043 in the Southern District of New York.
• Talcum powder / Johnson & Johnson ovarian cancer: Decades of litigation linking talc-based baby powder to ovarian cancer and mesothelioma; J&J’s bankruptcy restructuring continues to affect plaintiff recoveries.
• PFAS / “forever chemical” contamination in medications: Emerging litigation area involving pharmaceutical products and devices contaminated with PFAS compounds.
• GLP-1 weight loss drugs (semaglutide — Ozempic/Wegovy): Growing litigation alleging gastrointestinal injuries, including gastroparesis, bowel obstruction, and other serious complications from this rapidly growing drug class.

If you believe you have been harmed by any medication — whether or not it has been recalled or is part of active litigation — contact Wolf & Pravato for a free evaluation. We assess whether your injury qualifies for an existing MDL, a standalone product liability case in Florida state court, or a class action proceeding.

Pharmacy and Pharmacist Liability — When the Dispensing Error Is the Problem

Not all defective drug cases originate with the manufacturer. In some cases, the drug itself was properly designed and manufactured, but a pharmacy or pharmacist error caused the harm. Florida pharmacists and pharmacies are licensed and regulated by the Florida Board of Pharmacy under Chapter 465 F.S., and they owe a professional duty of care to their patients.

Pharmacy liability claims arise from:

• Wrong drug dispensed — filling a prescription with the incorrect medication
• Wrong dose — dispensing an incorrect strength of the correct drug
• Failure to identify dangerous drug interactions — pharmacists have a professional duty to screen prescriptions for interactions with other medications the patient is known to be taking
• Failure to counsel — Florida law requires pharmacists to offer counseling to new prescription patients; failure to do so that contributes to an injury may support a negligence claim
• Contaminated compounded drugs — pharmacies that compound custom medications carry heightened liability when contamination or preparation errors cause patient harm

Pharmacy liability claims are distinct from product liability claims against manufacturers and may involve both the individual pharmacist and the pharmacy chain. If your injury resulted from what you believe was a dispensing or counseling error at a Boynton Beach pharmacy, our attorneys evaluate these cases on the same contingency basis as pharmaceutical manufacturer cases.

Why Expert Witnesses Are Decisive in Florida Defective Drug Cases

Defective drug cases cannot be won without expert testimony. Unlike a car accident — where a jury can understand skid marks and intersection geometry — pharmaceutical liability requires the jury to understand organic chemistry, pharmacokinetics, clinical trial methodology, and regulatory toxicology. Every essential element of a drug defect claim requires an expert:

• Standard of care and design defect: A board-certified pharmacologist or pharmaceutical scientist must testify about the drug’s mechanism, the manufacturer’s design choices, and what a reasonably prudent pharmaceutical company should have done differently
• Manufacturing defect: A pharmaceutical manufacturing expert or quality systems specialist testifies about GMP (Good Manufacturing Practice) violations, contamination pathways, or production deviations
• Failure to warn: A regulatory affairs expert with FDA labeling experience testifies about what the manufacturer knew, when it knew it, and what warning it should have provided
• Causation: A toxicologist or physician expert in the relevant medical field must testify that the drug’s defect — the contamination, the design flaw, or the undisclosed risk — caused the specific injury you suffered. This general and specific causation analysis is often the most heavily contested issue in pharmaceutical litigation, as demonstrated by the Zantac MDL’s dismissal on Daubert/Rule 702 grounds
• Damages: Medical experts project future care needs; economists calculate lost earning capacity; life care planners document long-term care costs for catastrophic injuries

Wolf & Pravato maintains established relationships with qualified pharmacologists, toxicologists, FDA regulatory experts, and medical specialists who have served as expert witnesses in pharmaceutical product liability cases. Selecting and retaining the right experts — with the right credentials, the right methodology, and the ability to withstand aggressive Daubert challenges — is one of the most important things we do for clients in defective drug cases.

What Compensation Can You Recover in a Florida Defective Drug Case?

Florida’s product liability framework allows recovery of the full range of damages caused by a defective drug, without the plaintiff needing to prove negligence (under a strict liability theory). Compensable damages include:

Economic Damages

• Medical expenses: All treatment costs causally related to the drug injury — hospitalization, surgery, specialist care, medication, rehabilitation, and ongoing monitoring
• Future medical costs: Projected lifetime care expenses, calculated by a life care planner, for chronic conditions caused by the drug — such as ongoing oncology treatment for a drug-induced cancer
• Lost wages: Income lost during treatment and recovery from the drug injury
• Loss of future earning capacity: Where permanent impairment reduces the victim’s ability to work — calculated by a vocational expert and forensic economist
• Out-of-pocket costs: Prescription costs for the defective drug, travel to medical appointments, home modification, and other documented expenses

Non-Economic Damages

• Pain and suffering: Physical pain from the drug injury and its treatment — including chemotherapy, surgery, and chronic pain
• Mental anguish and emotional distress: Anxiety, depression, and psychological consequences of a serious drug-induced illness, particularly cancer diagnoses
• Loss of enjoyment of life: Inability to engage in activities, relationships, and the life the victim had before the drug injury
• Disfigurement: Scarring or physical alteration from surgical treatment of drug-induced conditions
• Loss of consortium: Damages to a spouse or partner for loss of companionship and support

Punitive Damages

In cases where a pharmaceutical manufacturer acted with gross negligence, deliberate concealment of known risks, or conscious disregard for patient safety, punitive damages are available under Florida law. Punitive damages go beyond compensating the victim — they are designed to punish egregious corporate conduct and deter future misconduct. Florida §768.72 F.S. governs punitive damage claims and requires a showing of clear and convincing evidence of the qualifying conduct. In high-profile pharmaceutical cases where internal documents show the company knew of a risk and chose not to disclose it, punitive damages can exceed compensatory damages significantly.

Wrongful Death

When a defective drug causes a patient’s death, the surviving family may bring a wrongful death claim under Florida’s Wrongful Death Act (§§768.16–768.26 F.S.). Wolf & Pravato handles wrongful death pharmaceutical cases for surviving spouses, children, and parents of Boynton Beach and Palm Beach County residents who died as a result of a defective medication. The same expert testimony requirements apply, and the same contingency fee structure — no fee unless we recover — covers wrongful death pharmaceutical cases.

Statute of Limitations for Defective Drug Claims in Florida — Know Your Deadline

⚠ Florida’s statute of limitations for defective drug claims is more complex than most personal injury cases. The applicable deadline depends on the legal theory and when the injury occurred or was discovered. Contact an attorney immediately — do not assume you have a fixed number of years from when you took the drug.

Strict Product Liability Claims: 4 Years

Under Florida Statute §95.11(3)(e), claims for injury caused by a defective product — including defective drugs pursued under a strict liability theory — carry a four-year statute of limitations. These four years were not changed by HB 837, which only reduced the limitations period for negligence-based claims. A drug injury victim pursuing strict product liability (design defect, manufacturing defect) generally has four years from when the injury occurred or was discovered.

Negligence-Based Drug Claims: 2 Years (Post-March 24, 2023)

If your claim is framed as a negligence theory — for example, a pharmacist’s failure to warn of a drug interaction, or a manufacturer’s negligent post-market surveillance — and the injury occurred on or after March 24, 2023, HB 837’s two-year limitations period applies under §95.11(4)(a) F.S. Most defective drug cases are pleaded under multiple theories simultaneously, meaning one deadline or the other may control depending on how the claim is framed.

The Discovery Rule and the 12-Year Statute of Repose

Under Florida’s discovery rule, the limitations period begins when the injured person knew or should have known that the drug caused their injury — not necessarily on the date they first took the drug or even the date of their diagnosis. For slow-developing drug injuries like cancer (which may not manifest for years or decades after drug exposure), the discovery rule can significantly extend the practical filing window.

However, Florida also imposes a 12-year statute of repose for product liability claims: no claim may be brought more than 12 years after the product was first delivered to its initial purchaser, regardless of when the injury was discovered — unless the manufacturer committed fraud or concealment, or the defect is latent and undiscoverable through reasonable inspection. In pharmaceutical cases where harm develops over decades of exposure, the statute of repose can be a significant barrier, and its exceptions (particularly fraud/concealment) often become central to the litigation.

⚠ PRACTICAL ADVICE: If you believe a drug caused your injury, do not try to calculate your limitations deadline yourself. These deadlines interact with the discovery rule, the statute of repose, MDL tolling agreements, and class action tolling in ways that require legal analysis. Contact Wolf & Pravato for a free evaluation — the call is free and the consequences of missing a deadline are permanent.

Why Choose Wolf & Pravato as Your Boynton Beach Defective Drug Lawyer?

There is no shortage of personal injury and mass tort law firms in South Florida, but Wolf & Pravato provides the level of personal attention, legal experience, and trial readiness that many high-volume firms cannot offer. Our attorneys are licensed to practice law in Florida and have decades of combined experience representing victims harmed by dangerous medications, defective drugs, and pharmaceutical negligence throughout Palm Beach County and across South Florida.

Defective drug cases are often complex and may involve large pharmaceutical companies, extensive medical records, and expert testimony. Our legal team carefully investigates each case, works with medical and scientific experts, and fights to hold drug manufacturers, distributors, and insurers accountable when unsafe medications cause serious injuries or long-term health complications.

We pursue compensation for medical expenses, lost income, pain and suffering, and other damages caused by harmful or recalled drugs.

Licensed and Verified Legal Representation

Experienced Florida personal injury attorney Richard Paul Pravato, a member in good standing with The Florida Bar since 1996, leads Wolf & Pravato. Attorney licensing and credentials can be verified through the official Florida Bar profile:

https://www.floridabar.org/mybarprofile/86150

Richard Pravato is also a Board Certified Civil Trial Attorney, a distinction awarded by The Florida Bar to attorneys who demonstrate exceptional knowledge, skill, and professionalism in civil trial law. This certification reflects our firm’s commitment to high-level advocacy in complex litigation, including defective drug and pharmaceutical injury cases.

When powerful drug companies and insurance providers try to avoid responsibility, having a board-certified trial lawyer on your side can make a significant difference in the outcome of your case.

What Our Clients Say About Us

“Brian and Vernae and Mr Pravato all did an excellent job handling my case in a timely manner! They also kept me informed and fought until the end! Brian was very informative!! The whole team, I couldn’t have asked for a better firm! HIGHLY RECOMMENDED.”

— Ja Morant

“Back in February I had an unfortunate accident and needed legal help. Jayne handled my case and she was amazing. I never had to guess what was happening because she always kept me updated by phone and email. The insurance and medical billing issues became complicated, but Wolf & Pravato fought for me every step of the way. They refused to let the insurance company take advantage of me, and we won. I highly recommend them to anyone who needs a personal injury attorney. They were fast, fair, and kept me informed throughout the entire process.”

— Madison Pando

Reference: https://share.google/vIaFmIWLh3vVcy1op

Contact Our Boynton Beach Defective Drug Lawyers — Free Consultation

If you or a family member has been harmed by a defective drug, a contaminated medication, or a pharmaceutical product that failed to warn you of its risks, do not wait. The statute of limitations begins running from the date of injury or discovery, and the evidence needed to establish your case (medical records, FDA regulatory history, company internal documents) must be secured before it disappears.

The Law Offices of Wolf & Pravato offer a free, confidential consultation for all defective drug cases. We will review your medical history, evaluate the drug’s regulatory and litigation status, assess whether your injury qualifies for an existing MDL or warrants individual Florida litigation, and tell you honestly what your case may be worth.

Call us at (844) 643-7200, visit our Boynton Beach office at 1375 Gateway Blvd., Boynton Beach, FL 33426, or contact us online. There is no fee unless we recover for you.

Frequently Asked Questions: Defective Drug Cases in Boynton Beach

How do I know if the drug that harmed me was actually defective?

You may not be able to determine this without legal and medical analysis. Signs that suggest a potential defective drug claim include: you were never warned of a side effect you experienced; the drug has since been recalled by the FDA or subject to an updated Black Box Warning; you have seen news coverage of litigation involving your medication; your injury developed in a pattern consistent with what other users have reported; or your prescribing doctor expressed surprise at your reaction and indicated it was not in the known risk profile. Wolf & Pravato offers a free consultation where we review your medical records and the drug’s regulatory history to assess whether a viable claim exists. You do not need to come with a pre-formed theory.

My drug was FDA-approved. Can I still sue?

Yes. FDA approval is not a complete defense against product liability claims under Florida law. FDA approval is regulatory evidence that the drug met the criteria for market approval — it is not a finding that the drug is perfectly safe under all circumstances or that the manufacturer discharged its duty to warn of all material risks. Florida courts allow drug liability claims to proceed notwithstanding FDA approval, particularly on failure-to-warn theories where the manufacturer had post-approval knowledge of risks that were not disclosed.

What is an MDL and will my case be part of one?

An MDL (Multi-District Litigation) is a federal court mechanism that consolidates thousands of similar cases before a single judge for pretrial purposes — discovery, expert battles, and bellwether trials. If you were harmed by a widely used drug that is the subject of national litigation (like Zantac, Tylenol/acetaminophen, or CPAP devices), your individual case may be transferred to the relevant MDL. In an MDL, you retain your own individual claim — it is not a class action. Your damages are your own, not averaged with thousands of others. Our attorneys evaluate whether your case belongs in an existing MDL, should be filed in Florida state court, or both.

The drug I took was generic. Can I still sue?

Generic drug liability claims face a significant legal obstacle due to federal preemption. The U.S. Supreme Court has held in Pliva v. Mensing and Mutual Pharmaceutical v. Bartlett that federal law preempts state-law failure-to-warn and design defect claims against generic manufacturers, because generic manufacturers are legally required to use the same labeling as the brand-name drug and cannot independently update warnings. However, manufacturing defect claims against generic manufacturers may still proceed, and brand-name manufacturer liability for a claim arising from the brand’s original design may extend to generic users in some circumstances under developing case law. Contact us to evaluate the specifics of your situation.

Can I join a class action against a drug company?

Potentially. Class actions are most appropriate when many plaintiffs have similar but relatively modest damages — for example, economic damages from purchasing a recalled drug. For plaintiffs with serious physical injuries (cancer, organ damage, neurological harm), individual lawsuits or MDL participation typically yield better recoveries than class actions, because individual damages are determined independently rather than shared across a large class. Our attorneys evaluate whether class action participation, MDL involvement, or individual litigation is the right path for your specific situation and injury.

What if I signed a consent form before taking the drug?

A consent form — whether from your prescribing physician or a clinical trial — does not bar a product liability claim against the drug manufacturer. The consent form documents what the prescribing doctor or trial coordinator disclosed to you; it does not address what the manufacturer knew and failed to disclose to anyone. If the manufacturer withheld material safety information from prescribers, your claim against the manufacturer is not waived by a patient consent form you signed with a different party.

How does Wolf & Pravato charge for defective drug cases?

We handle all defective drug and product liability cases on a pure contingency fee basis — you pay no attorney fees unless and until we recover compensation for you. There are no upfront costs, no hourly billing, and no fee if we do not win. This means access to our team, our expert network, and our litigation resources costs you nothing out of pocket. Contact our Boynton Beach office at (844) 643-7200 or visit us at 1375 Gateway Blvd., Boynton Beach, FL 33426 for a free case evaluation.